<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02796157</url>
  </required_header>
  <id_info>
    <org_study_id>1-2016-0025</org_study_id>
    <nct_id>NCT02796157</nct_id>
  </id_info>
  <brief_title>A Randomized Comparison of Clinical Outcomes Between Everolimus-eluting Bioresorbable Vascular Scaffold Versus Everolimus-eluting Metallic Stent in Long Coronary Lesions</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PCI of diffuse long coronary lesions still remains challenging because of relatively high
      risk of in-stent restenosis and stent thrombosis compared to short coronary lesions. The
      purpose of the study is to compare an incidence of composite of major adverse cardiovascular
      events (MACEs) at 1 year between Absorb everolimus-eluting BVS and Xience EES after coronary
      intervention in long lesions.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of composite of major adverse cardiovascular events</measure>
    <time_frame>1 year after PCI</time_frame>
    <description>Cardiac death, nonfatal myocardial infarction (MI), stent thrombosis and target-lesion revascularization (TLR)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">950</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>absorb arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PCI with Absorb everolimus-eluting bioresorbable vascular scaffold</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xience arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PCI with Xience everolimus-eluting metallic stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PCI with Absorb everolimus-eluting bioresorbable vascular scaffold</intervention_name>
    <description>Patients allocated to this arm will undergone PCI with Absorb everolimus-eluting bioresorbable vascular scaffold. It will be allowed to used multiple stents for a long coronary lesion.</description>
    <arm_group_label>absorb arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PCI with Xience everolimus-eluting metallic stent</intervention_name>
    <description>Patients allocated to this arm will undergone PCI with Xience everolimus-eluting metallic stent. It will be allowed to used multiple stents for a long coronary lesion.</description>
    <arm_group_label>Xience arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 19-85 years

          -  Patients with ischemic heart disease requiring PCI

          -  Significant coronary de novo lesion (stenosis &gt;50% by quantitative angiographic
             analysis) requiring stent â‰¥28 mm in length based on angiographic estimation

          -  Reference vessel diameter of 2.5 to 3.75 mm by operator assessment

        Exclusion Criteria:

          -  Acute myocardial infarction within 48 hours with unstable hemodynamics requiring
             pharmacologic or mechanical support

          -  Complex coronary morphology including left main disease and bifurcation lesion
             requiring two-stent technique

          -  Contraindication or hypersensitivity to anti-platelet agents or contrast media

          -  Treated with any metallic stent or BVS within 3 months at other vessel

          -  Cardiogenic shock

          -  Left ventricular ejection fraction &lt;40%

          -  Pregnant women or women with potential childbearing

          -  Inability to follow the patient over the period of 1 year after enrollment, as
             assessed by the investigator

          -  Inability to understand or read the informed content
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MYEONG-KI HONG, MD</last_name>
      <phone>82-2-2228-8458</phone>
      <email>MKHONG61@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2016</study_first_submitted>
  <study_first_submitted_qc>June 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2016</study_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bioresorbable vascular scaffold, drug eluting stent, coronary artery disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

